Journal of VitreoRetinal Diseases最新文献

筛选
英文 中文
From the Editor-in-Chief. 主编的话
IF 0.5
Journal of VitreoRetinal Diseases Pub Date : 2024-09-20 eCollection Date: 2024-09-01 DOI: 10.1177/24741264241278446
Timothy G Murray
{"title":"From the Editor-in-Chief.","authors":"Timothy G Murray","doi":"10.1177/24741264241278446","DOIUrl":"https://doi.org/10.1177/24741264241278446","url":null,"abstract":"","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11418728/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142349353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Update on Retinal Drug Safety: Proceedings of the ASRS ReST Committee Webinar Part 1. 视网膜药物安全的最新进展:ASRS ReST 委员会网络研讨会第一部分会议记录。
IF 0.5
Journal of VitreoRetinal Diseases Pub Date : 2024-08-22 eCollection Date: 2024-09-01 DOI: 10.1177/24741264241261441
Jessica M Girgis, Caroline R Baumal, Andre J Witkin, Lejla Vajzovic, Roger A Goldberg, Peter Kaiser, J Fernando Arevalo, Netan Choudhry, Eric Schneider, Homayoun Tabandeh, Robert Wong
{"title":"Update on Retinal Drug Safety: Proceedings of the ASRS ReST Committee Webinar Part 1.","authors":"Jessica M Girgis, Caroline R Baumal, Andre J Witkin, Lejla Vajzovic, Roger A Goldberg, Peter Kaiser, J Fernando Arevalo, Netan Choudhry, Eric Schneider, Homayoun Tabandeh, Robert Wong","doi":"10.1177/24741264241261441","DOIUrl":"https://doi.org/10.1177/24741264241261441","url":null,"abstract":"<p><p><b>Purpose:</b> To review the first Research and Safety in Therapeutics (ReST) Committee webinar and summarize the most current recommendations regarding diagnosis and management. <b>Methods:</b> The ReST Committee is comprised of members of the American Society of Retina Surgeons (ASRS). At regular internal meetings, safety issue reports from the website are reviewed. A webinar series was started in 2021 to update members on multiple relevant potential safety events. <b>Results:</b> Topics reviewed in the webinar included pentosan polysulfate sodium (Elmiron) maculopathy, intraocular pressure elevation reported with the aflibercept prefilled syringe (PFS), and brolucizumab-associated inflammation with occlusive retinal vasculitis. Retinal toxicity related to intraoperative medications was reviewed, including hemorrhagic occlusive retinal vasculitis after intraocular vancomycin, dilution errors with intravitreal aminoglycosides, inadvertent overdoses of cefuroxime after cataract surgery, and toxic posterior segment syndrome after dropless cataract surgery using compounded triamcinolone-moxifloxacin. Indocyanine green toxicity has been reported after its use as an adjuvant during macular hole surgery. <b>Conclusions:</b> The past decade has seen advances in retinal pharmaceuticals and drug-delivery devices. The ASRS ReST Committee collects data from its website reporting system to inform members about up-to-date pharmaceutical and device safety concerns. Recently, a webinar was used to inform members of pigmentary maculopathy associated with pentosan polysulfate sodium, safety regarding the aflibercept PFS, intraocular inflammation and occlusive retinal vasculitis secondary to brolucizumab, and retinal toxicity from intraoperative ocular medications.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11418662/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142336452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Extended Intraocular Drug-Delivery Platforms for the Treatment of Retinal and Choroidal Diseases. 用于治疗视网膜和脉络膜疾病的扩展眼内给药平台。
IF 0.5
Journal of VitreoRetinal Diseases Pub Date : 2024-08-22 eCollection Date: 2024-09-01 DOI: 10.1177/24741264241267065
Charles C Wykoff, Baruch D Kuppermann, Carl D Regillo, Margaret Chang, Seenu M Hariprasad, Jay S Duker, Syed Altaf, Saïd Saïm
{"title":"Extended Intraocular Drug-Delivery Platforms for the Treatment of Retinal and Choroidal Diseases.","authors":"Charles C Wykoff, Baruch D Kuppermann, Carl D Regillo, Margaret Chang, Seenu M Hariprasad, Jay S Duker, Syed Altaf, Saïd Saïm","doi":"10.1177/24741264241267065","DOIUrl":"https://doi.org/10.1177/24741264241267065","url":null,"abstract":"<p><p><b>Purpose:</b> To review sustained-release intraocular platforms used to treat diseases of the retina and choroid. <b>Methods:</b> A literature review of the current applications of biomaterials for sustained-release therapy in retinal and choroidal diseases was performed. <b>Results:</b> Retinal and choroidal diseases, such as neovascular age-related macular degeneration (nAMD), diabetic retinopathy (DR), diabetic macular edema (DME), and uveitis, are commonly treated using intravitreal (IVT) therapies that require frequent IVT injections. Multiple sustained-release options for IVT therapy have been approved by the US Food and Drug Administration for the treatment of inflammatory eye diseases, including noninfectious uveitis, infectious diseases, and exudative retinal diseases (eg, retinal venous occlusive disease and DME) using drugs such as fluocinolone acetonide, ganciclovir, and dexamethasone. The platforms for these drugs are biodegradable or nonbiodegradable. They use biomaterials such as polymers and hydrogels and are typically implanted surgically or injected into the vitreous, where they release the drug gradually over months or years. Building on these technologies, novel platforms are being studied that are intended to treat conditions including nAMD, DR, DME, and uveitis. These platforms are being tested for their safety, efficacy, and ability to reduce the injection and visit burden. <b>Conclusions:</b> Multiple sustained-release ocular drug-delivery platforms are currently commercially available, and many new sustained-release IVT platforms are being investigated. The hope is that meaningfully reducing the injection burden by extending intervals between treatments while maintaining optimal efficacy will improve long-term outcomes.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11418737/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142349351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
2024 Distinguished Contributor Awards. 2024 杰出贡献奖。
IF 0.5
Journal of VitreoRetinal Diseases Pub Date : 2024-08-08 eCollection Date: 2024-07-01 DOI: 10.1177/24741264241263405
{"title":"2024 Distinguished Contributor Awards.","authors":"","doi":"10.1177/24741264241263405","DOIUrl":"https://doi.org/10.1177/24741264241263405","url":null,"abstract":"","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11323515/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141988221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Successful Treatment of Central Retinal Artery Occlusion With Tissue Plasminogen Activator Followed by Recurrent Retinal Ischemia 使用组织蛋白酶原激活剂成功治疗视网膜中央动脉闭塞后复发性视网膜缺血
IF 0.5
Journal of VitreoRetinal Diseases Pub Date : 2024-08-08 DOI: 10.1177/24741264241267376
Jerry Hsu, Jeffrey Brown, Adnan Mallick, Michael Fara, R. D. De Leacy, Richard B. Rosen, Robin N. Ginsburg, G. M. Lema
{"title":"Successful Treatment of Central Retinal Artery Occlusion With Tissue Plasminogen Activator Followed by Recurrent Retinal Ischemia","authors":"Jerry Hsu, Jeffrey Brown, Adnan Mallick, Michael Fara, R. D. De Leacy, Richard B. Rosen, Robin N. Ginsburg, G. M. Lema","doi":"10.1177/24741264241267376","DOIUrl":"https://doi.org/10.1177/24741264241267376","url":null,"abstract":"Purpose: To describe the use of intra-arterial tissue plasminogen activator (tPA) to treat central retinal artery occlusion (CRAO). Methods: A case and its findings were analyzed. Results: A 45-year-old man was diagnosed with a CRAO and had cerebral angiography and treatment with intra-arterial tPA. After treatment, follow-up included optical coherence tomography (OCT), fundus photography, fluorescein angiography, and OCT angiography. The visual acuity (VA) improved from hand motions to 20/30 immediately after fibrinolysis. A vascular occlusion event the next day resulted in a decrease in VA to 20/400. After initiation of dual antiplatelet therapy, the patient’s VA improved to 20/20. As the retina recovered, the evolution of retinal ischemic changes to a finding similar to paracentral acute middle maculopathy was seen on imaging. Conclusions: This is the first report describing a patient safely started on dual antiplatelet therapy that led to vision improvement after initial treatment with intra-arterial tPA for a CRAO resulted in recurrent vision loss.","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141927966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
From the Editor-in-Chief. 主编的话
IF 0.5
Journal of VitreoRetinal Diseases Pub Date : 2024-08-08 eCollection Date: 2024-07-01 DOI: 10.1177/24741264241258580
Timothy G Murray
{"title":"From the Editor-in-Chief.","authors":"Timothy G Murray","doi":"10.1177/24741264241258580","DOIUrl":"10.1177/24741264241258580","url":null,"abstract":"","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11323519/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141988223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Outcomes of Pars Plana Vitrectomy and Polytetrafluoroethylene (Gore-Tex) Scleral Fixation of a Monofocal Aspheric Intraocular Lens (Akreos AO60). 玻璃体旁切除术和聚四氟乙烯(Gore-Tex)巩膜固定单焦点非球面眼内透镜(Akreos AO60)的临床效果。
IF 0.5
Journal of VitreoRetinal Diseases Pub Date : 2024-08-02 eCollection Date: 2024-09-01 DOI: 10.1177/24741264241260094
Amit V Mishra, Rosanna Martens, Graeme K Loh, Rizwan Somani, Mark D J Greve, Mark E Seamone
{"title":"Clinical Outcomes of Pars Plana Vitrectomy and Polytetrafluoroethylene (Gore-Tex) Scleral Fixation of a Monofocal Aspheric Intraocular Lens (Akreos AO60).","authors":"Amit V Mishra, Rosanna Martens, Graeme K Loh, Rizwan Somani, Mark D J Greve, Mark E Seamone","doi":"10.1177/24741264241260094","DOIUrl":"https://doi.org/10.1177/24741264241260094","url":null,"abstract":"<p><p><b>Purpose:</b> To evaluate the visual outcomes and complications with a polytetrafluoroethylene (Gore-Tex)-fixated intraocular lens (IOL) (Akreos AO60, Bausch + Lomb). <b>Methods:</b> Eyes with inadequate capsule support for in-the-bag IOL implantation had pars plana vitrectomy (PPV) and IOL placement at a single center. The main outcome measures were the postoperative visual acuity (VA) and complication rates. <b>Results:</b> During the study, 783 surgeries were performed. The mean visual acuity gain was 28.5 Early Treatment Diabetic Retinopathy Study letters (<i>P</i> < .01), with a mean time to best VA of 3.05 months. Statistical hypotony (intraocular pressure <6.5 mm Hg) was present in 214 cases (27.3%), and clinical features of hypotony were present in 46 cases. Five percent of the complications were directly related to the IOL. There were 3 cases of IOL opacification, 2 with silicone oil endotamponade and 1 with perfluoropropane endotamponade. <b>Conclusions:</b> PPV with Akreos IOL implantation was an effective technique for secondary IOL placement. Complications directly related to the IOL were uncommon.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2024-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11425783/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142349350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impaired Visual Function in Posterior Vitreous Detachment Assessed With the Active-Learning Quantitative Contrast Sensitivity Function Test. 通过主动学习定量对比敏感度功能测试评估后玻璃体脱落的视觉功能受损情况
IF 0.5
Journal of VitreoRetinal Diseases Pub Date : 2024-07-30 eCollection Date: 2024-09-01 DOI: 10.1177/24741264241259245
Peyman Razavi, Filippos Vingopoulos, Mauricio Garcia, Francesco Romano, Hanna Choi, Xinyi Ding, Itika Garg, Grace Baldwin, Rebecca Zeng, Matthew Finn, Augustine Bannerman, Hannah Wescott, Leo A Kim, Deeba Husain, Demetrios Vavvas, John B Miller
{"title":"Impaired Visual Function in Posterior Vitreous Detachment Assessed With the Active-Learning Quantitative Contrast Sensitivity Function Test.","authors":"Peyman Razavi, Filippos Vingopoulos, Mauricio Garcia, Francesco Romano, Hanna Choi, Xinyi Ding, Itika Garg, Grace Baldwin, Rebecca Zeng, Matthew Finn, Augustine Bannerman, Hannah Wescott, Leo A Kim, Deeba Husain, Demetrios Vavvas, John B Miller","doi":"10.1177/24741264241259245","DOIUrl":"10.1177/24741264241259245","url":null,"abstract":"<p><p><b>Introduction:</b> To investigate whether there is visual function impairment in patients with posterior vitreous detachment (PVD) using the active-learning quantitative contrast sensitivity function test. <b>Methods:</b> In this cross-sectional study, contrast sensitivity was measured in eyes with PVD and eyes without PVD using the quantitative contrast sensitivity function algorithm on the Adaptive Sensory Technology platform. Outcomes included the area under the log contrast sensitivity function curve, contrast acuity, and contrast sensitivity thresholds at 1 to 18 cycles per degree (cpd). Snellen visual acuity (VA) was also measured. Mixed-effects multiple linear regression analyses were performed to evaluate the association between the presence of PVD and visual function, controlling for age and lens status. <b>Results:</b> The cohort comprised 232 healthy eyes of 205 participants; of these, 80 eyes of 69 patients had PVD. There was no significant association between VA and PVD presence. However, PVD was significantly associated with decreased contrast sensitivity thresholds at 1.5 cpd (β, -0.058; <i>P</i> = .003) and 3 cpd (β, -0.067; <i>P</i> = .004). Contrast sensitivity thresholds at lower (1 cpd) or higher (6, 12, 18 cpd) spatial frequencies did not significantly correlate with PVD presence. Even in the subgroup of symptomatic PVD eyes, VA was not significantly decreased, while quantitative contrast sensitivity function outcomes showed visual function deficits at low spatial frequencies (1.5 cpd and 3 cpd). <b>Conclusions:</b> Contrast sensitivity measured with the quantitative contrast sensitivity function test showed visual function deficits in eyes with PVD that would have been missed with VA testing alone. Incorporating this test in the retina clinic might offer a more comprehensive functional assessment of eyes with PVD, serving as an adjunct outcome metric in clinical decision-making.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2024-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11439180/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142349354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adverse Events Associated With 3 Vitrectomy Platforms Reported to the US FDA MAUDE Database. 向美国 FDA MAUDE 数据库报告的 3 种玻璃体切除术平台的相关不良事件。
IF 0.5
Journal of VitreoRetinal Diseases Pub Date : 2024-07-28 eCollection Date: 2024-09-01 DOI: 10.1177/24741264241264356
Hannah H Hwang, Benjamin W Botsford, Tamara L Lenis, Mohammad Ali Sadiq, Abdallah Mahrous, Anton Orlin, Szilard Kiss, Donald J D'Amico, Sarah H Van Tassel, Kyle D Kovacs
{"title":"Adverse Events Associated With 3 Vitrectomy Platforms Reported to the US FDA MAUDE Database.","authors":"Hannah H Hwang, Benjamin W Botsford, Tamara L Lenis, Mohammad Ali Sadiq, Abdallah Mahrous, Anton Orlin, Szilard Kiss, Donald J D'Amico, Sarah H Van Tassel, Kyle D Kovacs","doi":"10.1177/24741264241264356","DOIUrl":"https://doi.org/10.1177/24741264241264356","url":null,"abstract":"<p><p><b>Purpose:</b> To identify and describe adverse events (AEs) observed with real-world use of the following 3 vitrectomy platforms: Constellation (Alcon), Enhancing Visual Acuity (EVA, Dutch Ophthalmic Research Center), and Stellaris (Bausch + Lomb). <b>Methods:</b> All reports submitted to the US Food and Drug Administration's Manufacturer and User Facility Device Experience (MAUDE) database between January 2010 and November 2021 that were associated with the 3 vitrectomy platforms were analyzed. Each report was reviewed for AEs or consequences and the type of complication noted. Duplicates and reports with an inadequate narrative to categorize the event were excluded. A descriptive analysis was performed for the prevalence of device-specific issues within each platform. <b>Results:</b> The analysis included 2534 reports (1738 Constellation, 117 EVA, 679 Stellaris). Overall, the most commonly reported complications involved the vitrectomy probe (n = 957 [37.8%]) and the central processing unit (n = 368 [14.5%]). Differences in the distribution of AEs among the platforms were noted, with vitrectomy probe issues being the most reported events for the Constellation and Stellaris and infusion issues for the EVA. Infusion issues most frequently led to reports of patient harm with the Constellation (31/1738 [1.8%]) and EVA (7/116 [6.0%]), while issues with the vitrectomy probe were reported with the Stellaris (11/679 [1.6%]). <b>Conclusions:</b> An analysis of real-world data in the MAUDE database highlighted the spectrum of device-specific AEs of greatest relevance to surgical practice. Familiarity with potential device complications will help minimize harm to patients.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2024-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11418686/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142349348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessment of Macular Hole Closure Speed Using Trans-tamponade OCT and 3-Dimensional Macular Hole Segmentation in the DISCOVER Study. 在 DISCOVER 研究中使用经填塞 OCT 和三维黄斑孔分割评估黄斑孔闭合速度。
IF 0.5
Journal of VitreoRetinal Diseases Pub Date : 2024-07-28 eCollection Date: 2024-09-01 DOI: 10.1177/24741264241263172
Yavuz Cakir, Antoine Sassine, Karen Matar, Reem Amine, Jamie Reese, Sunil K Srivastava, Justis P Ehlers
{"title":"Assessment of Macular Hole Closure Speed Using Trans-tamponade OCT and 3-Dimensional Macular Hole Segmentation in the DISCOVER Study.","authors":"Yavuz Cakir, Antoine Sassine, Karen Matar, Reem Amine, Jamie Reese, Sunil K Srivastava, Justis P Ehlers","doi":"10.1177/24741264241263172","DOIUrl":"https://doi.org/10.1177/24741264241263172","url":null,"abstract":"<p><p><b>Introduction:</b> To explore opportunities for individualized postoperative positioning duration in macular hole (MH) surgery. <b>Methods</b>: This post hoc analysis comprised eyes that had full-thickness MH (FTMH) repair in the prospective DISCOVER intraoperative optical coherence tomography (OCT) study. Preoperative spectral-domain OCT (SD-OCT) and postoperative day 1 (POD1) trans-tamponade OCT were analyzed. Preoperative SD-OCT macular cubes were imported and analyzed using a machine learning-enhanced segmentation platform. Nine preoperative segmentation parameters were analyzed (maximum foveal height, apex area, base area, central foveal area, maximum apex diameter, maximum base diameter, maximum depth, minimum foveal width, volume). In addition, 2 new metrics-the macular hole index and tractional hole index-were calculated. POD1 trans-tamponade OCTs were obtained and evaluated for hole closure. <b>Results</b>: Of the 66 eyes with an FTMH, 16 (24%) had a chronic MH and 5 (8%) were reoperations from FTMH nonclosure after previous surgery. Nine eyes (14%) had an open MH on POD1 trans-tamponade OCT (6 chronic MHs [66%]; 2 reoperations [22%]); the remaining 57 MHs (86%) were closed. Multiple segmentation parameters were significantly associated with POD1 closure. <b>Conclusions</b>: Volumetric MH measurements and trans-tamponade POD1 OCT closure status are important in predicting MH closure speed and the need for postoperative positioning. Individualized positioning duration in MH could lower perioperative morbidity and vastly enhance quality of life.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2024-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11418717/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142349349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信